Risk management of risk management: Combining proton pump inhibitors with low-dose aspirin

References

• HawkeyCJCOX-2 chronologyGut2005541509151416227351
   PubMed Web of Science ®Google Scholar
• GibsonAC Oh willow, don’t weep. Available at: http://www.botgard.ucla.edu/html/botanytextbooks/economicbotany/salix/. Accessed Jun 10, 2010.
   Google Scholar
• JonesRNonsteroidal anti-inflammatory drug prescribing: Past, present and futureAm J Med20011104S7S11165987
   PubMedGoogle Scholar
• JackDBOne hundred years of aspirinLancet19973504374399259670
   PubMed Web of Science ®Google Scholar
• DreserHPharmacologisches uber aspirin (acetylsalicyl saure)Pflugers Arch189976306
   Google Scholar
• Bayer AspirinHistory of aspirin2010 Available at: http://www.bayeraspirin.com/pain/asp_history.htm. Accessed Jun 10, 2010.
   Google Scholar
• CravenLLExperiences with aspirin (acetylsalicylic acid) in the non-specific prophylaxis of coronary thrombosisMiss Valley Med J195375384413013156
   PubMedGoogle Scholar
• O’BrienJREffects of salicylates on human plateletsLancet196817797834171129
   PubMed Web of Science ®Google Scholar
• ElwoodPCCochraneALBurrMLA randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarctionBr Med J197414364404593555
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ CollaborationCollaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ2002324718611786451
   PubMed Web of Science ®Google Scholar
• ChenZMSandercockPPanHCIndications for early aspirin use in acute ischemic stroke: A combined analysis of 40 000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. On behalf of the CAST and IST collaborative groupsStroke2000311240124910835439
   PubMed Web of Science ®Google Scholar
• BaigentCBlackwellLCollinsRAntithrombotic Trialists’ (ATT) CollaborationAspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trialsLancet20093731849186019482214
   PubMed Web of Science ®Google Scholar
• ZhangCSunAZhangPAspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysisDiabetes Res Clin Pract20108721121819853947
   PubMed Web of Science ®Google Scholar
• PignoneMAlbertsMJColwellJAAspirin for primary prevention of cardiovascular events in people with diabetes. A position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology FoundationCirculation20101212694270120508178
   PubMed Web of Science ®Google Scholar
• FowkesFGPriceJFStewartMCAspirin for Asymptomatic Atherosclerosis TrialistsAspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: A randomized controlled trialJAMA201030384184820197530
   PubMed Web of Science ®Google Scholar
• BergerJSAspirin as preventive therapy in patients with asymptomatic vascular diseaseJAMA201030388088220197537
   PubMed Web of Science ®Google Scholar
• BergerJSKrantzMJKittelsonJMHiattWRAspirin for the prevention of cardiovascular events in patients with peripheral artery disease: A meta-analysis of randomized trialsJAMA20093011909191919436018
   PubMed Web of Science ®Google Scholar
• KrasopoulosGBristerSJBeattieWSBuchananMRAspirin “resistance” and risk of cardiovascular morbidity: Systematic review and meta-analysisBMJ200833619519818202034
   PubMed Web of Science ®Google Scholar
• AjjanRStoreyRFGrantPJAspirin resistance and diabetes mellitusDiabetologia20085138539018197397
   PubMed Web of Science ®Google Scholar
• DerrySLokeYKRisk of gastrointestinal haemorrhage with long term use of aspirin: Meta-analysisBMJ20003211183118711073508
   PubMed Web of Science ®Google Scholar
• LanasAPerez-AisaMAFeuFInvestigators of the Asociación Española de Gastroenterología (AEG)A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal anti-inflammatory drug useAm J Gastroenterol20051001685169316086703
   PubMed Web of Science ®Google Scholar
• DouthwaiteAHLintottSAMGastroscopic observation of the effect of aspirin and certain other substances on the stomachLancet1938212221225
   Google Scholar
• VonkemanHEvan de LaarMANonsteroidal anti-inflammatory drugs: Adverse effects and their preventionSemin Arthritis Rheum20103929431218823646
   PubMed Web of Science ®Google Scholar
• ManesGBalzanoAMaronePLionielloMMoscaSAppropriateness and diagnostic yield of upper gastrointestinal endoscopy in an open-access endoscopy system: A prospective observational study based on the Maastricht guidelinesAliment Pharmacol Ther20021610511011856084
   PubMed Web of Science ®Google Scholar
• YeomansNDLanasAITalleyNJPrevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirinAliment Pharmacol Ther20052279580116225488
   PubMed Web of Science ®Google Scholar
• KellyJPKaufmanDWJurgelonJMSheehanJKoffRSShapiroSRisk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered productLancet1996348141314168937281
   PubMed Web of Science ®Google Scholar
• WallaceJLNonsteroidal anti-inflammatory drugs and gastroenteropathy: The second hundred yearsGastroenterology1997112100010169041264
   PubMed Web of Science ®Google Scholar
• ShiotaniAKamadaTHarumaKLow-dose aspirin induced gastrointestinal diseases: Past, present, and futureJ Gastroenterol20084358158818709479
   PubMed Web of Science ®Google Scholar
• GrahamDYSmithJLDobbsSMGastric adaptation occurs with aspirin administration in manDig Dis Sci198323166600426
   PubMed Web of Science ®Google Scholar
• GeallMGPhillipsSFSummerskillWHProfile of gastric potential difference in man. Effects of aspirin, alcohol, bile, and endogenous acidGastroenterology1970584374435437999
   PubMed Web of Science ®Google Scholar
• LaineLMallerESYuCQuanHSimonTUlcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: A double blind trialGastroenterology2004127359402
   Web of Science ®Google Scholar
• WeismanSMGrahamDYEvaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular eventsArch Intern Med20021622197220212390062
   PubMed Web of Science ®Google Scholar
• McQuaidKRLaineLSystematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trialsAm J Med200611962463816887404
   PubMed Web of Science ®Google Scholar
• SorensenHTMellemkjaerLBlotWJRisk of upper gastrointestinal bleeding associated with use of low-dose aspirinAm J Gastroenterol2000952218222411007221
   PubMed Web of Science ®Google Scholar
• SinghGRosen RameyDNSAID-induced gastrointestinal complications: The ARAMIS perspective – 1997J Rheumatol Suppl1998518169596549
   PubMedGoogle Scholar
• US Preventive Services Task ForceAspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statementAnn Intern Med200915039640419293072
   PubMed Web of Science ®Google Scholar
• HallasJDallMAndriesAUse of single and combined anti-thrombotic therapy and risk of serious upper gastrointestinal bleeding: Population based case-control studyBMJ200633372616984924
   PubMed Web of Science ®Google Scholar
• LanasAScheimanJLow-dose aspirin and upper gastrointestinal damage: Epidemiology, prevention and treatmentCurr Med Res Opin20072316317317257477
   PubMed Web of Science ®Google Scholar
• BhattDLScheimanJAbrahamNSAmerican College of Cardiology Foundation Task Force on Clinical Expert Consensus DocumentsACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus DocumentsCirculation20081181894190918836135
   PubMed Web of Science ®Google Scholar
• LanasAGarcía-RodríguezLAArroyoMTAsociación Española de GastroenterologíaRisk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinationsGut2006551731173816687434
   PubMed Web of Science ®Google Scholar
• SteinhublSRBhattDLBrennanDMCHARISMA InvestigatorsAspirin to prevent cardiovascular disease: The association of aspirin dose and clopidogrel with thrombosis and bleedingAnn Intern Med200915037938619293071
   PubMed Web of Science ®Google Scholar
• HuntRHBazzoliFShould NSAID/low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healingAliment Pharmacol Ther20041991614725573
   PubMed Web of Science ®Google Scholar
• ChanFKGrahamDYPrevention of non-steroidal anti-inflammatory drug gastrointestinal complications – review and recommendations based on risk assessmentAliment Pharmacol Ther2004191051106115142194
   PubMed Web of Science ®Google Scholar
• HuangJQSridharSHuntRHRole of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease, a meta-analysisLancet2002359142211809181
   PubMed Web of Science ®Google Scholar
• VergaraMCatalánMGisbertJPCalvetXMeta-analysis, role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID usersAliment Pharmacol Ther2005211411141815948807
   PubMed Web of Science ®Google Scholar
• LanasAFuentesJBenitoRSerranoPBajadorESáinzRHelicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirinAliment Pharmacol Ther20021677978611929396
   PubMed Web of Science ®Google Scholar
• ChanFKChungSCSuenBYPreventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxenN Engl J Med200134496797311274623
   PubMed Web of Science ®Google Scholar
• LaiKCLamSKChuKMLansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin useN Engl J Med20023462033203812087138
   PubMed Web of Science ®Google Scholar
• RostomADubeCWellsGPrevention of NSAID-induced gastrointestinal ulcersCochrane Database Syst Rev20022CD00229612519573
   PubMedGoogle Scholar
• DonnellyMTGoddardAFFilipowiczBMorantSVShieldMJHawkeyCJLow-dose misoprostol for the prevention of low-dose aspirin-induced gastroduodenal injuryAliment Pharmacol Ther20001452953410792114
   PubMed Web of Science ®Google Scholar
• TahaASMcCloskeyCPrasadRBezlyakVFamotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): A Phase III, randomised, double-blind, placebo-controlled trialLancet200937411912519577798
   PubMed Web of Science ®Google Scholar
• LanasAGarcía-RodríguezLAArroyoMTInvestigators of the Asociación Española de Gastroenterología (AEG)Effect of anti-secretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulantsAm J Gastroenterol200710250751517338735
   PubMed Web of Science ®Google Scholar
• LanasABajadorESerranoPNitrovasodilators, low-dose aspirin, other nonsteroidal anti-inflammatory drugs, and the risk of upper gastrointestinal bleedingN Engl J Med200034383483910995862
   PubMed Web of Science ®Google Scholar
• SimonBElsnerHMüllerPProtective effect of omeprazole against low-dose acetylsalicylic acid. Endoscopic controlled double-blind study in healthy subjectsArzneimittelforschung1995457017037646574
   PubMed Web of Science ®Google Scholar
• MüllerPFuchsWSimonBStudies on the protective effect of lansoprazole on human gastric mucosa against low-dose acetylsalicylic acid. An endoscopic controlled double-blind studyArzneimittelforschung1997477587609281302
   PubMed Web of Science ®Google Scholar
• YeomansNLanasALabenzJEfficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirinAm J Gastroenterol20081032465247318637091
   PubMed Web of Science ®Google Scholar
• NgFHWongSYLamKFFamotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosionsGastroenterology2010138828819837071
   PubMed Web of Science ®Google Scholar
• SungJJLauJYChingJYContinuation of low-dose aspirin therapy in peptic ulcer bleeding: A randomized trialAnn Intern Med20101521919949136
   PubMed Web of Science ®Google Scholar
• WürtzMGroveELKristensenSDThe antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery diseaseHeart20109636837119910291
   PubMed Web of Science ®Google Scholar
• HarkerLABoisselJPPilgrimAJGentMComparative safety and tolerability of clopidogrel and aspirin: Results from CAPRI. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic eventsDrug Saf19992132533510514023
   PubMed Web of Science ®Google Scholar
• AndersonJLAdamsCDAntmanEMAmerican College of CardiologyAmerican Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarctionCirculation2007116e138e304
   Web of Science ®Google Scholar
• ChanFKChingJYHungLCClopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleedingN Engl J Med200535223824415659723
   PubMed Web of Science ®Google Scholar
• LaiKCChuKMHuiWMEsomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complicationsClin Gastroenterol Hepatol2006486086516797240
   PubMed Web of Science ®Google Scholar
• YusufSZhaoFMehtaSRChrolaviciusSTognoniGFoxKKClopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevationN Engl J Med200134549450211519503
   PubMed Web of Science ®Google Scholar
• JuurlinkDNGomesTKoDTA population-based study of the drug interaction between proton pump inhibitors and clopidogrelCMAJ200918071371819176635
   PubMed Web of Science ®Google Scholar
• GilardMArnaudBCornilyJCInfluence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin, the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) studyJ Am Coll Cardiol20085125626018206732
   PubMed Web of Science ®Google Scholar
• Siller-MatulaJMSpielAOLangIMKreinerGChristGJilmaBEffects of pantoprazole and esomeprazole on platelet inhibition by clopidogrelAm Heart J2009157148.e1e519081411
   PubMed Web of Science ®Google Scholar
• LaineLHennekensCProton pump inhibitor and clopidogrel interaction, fact or fiction?Am J Gastroenterol2009105344119904241
   PubMed Web of Science ®Google Scholar